CDA | Evidence Driven
CDA | Evidence Driven

Tenecteplase for Acute Ischemic Stroke

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1469-000
Effective finish date:

Question

  1. What is the cost-effectiveness of tenecteplase compared with alteplase for acute ischemic stroke?

Key Message

Both included economic evaluation studies (1 from Iran and 1 from Australia) found that tenecteplase was the dominant treatment strategy (i.e., lower costs and higher benefit) compared with alteplase over a lifetime horizon.

Files

Tenecteplase for Acute Ischemic Stroke View PDF
Last Updated : February 9, 2023